Dr. Guo Yongchao, chairman of Uni-medica, was invited to share the theme of "Newborn Genetic Screening for Inherited Diseases"

2023-06-21

In order to strengthen the management of neonatal inherited metabolic diseases and improve the screening level of neonatal inherited metabolic diseases, the 2023 Guangdong Province training course on the standardized diagnosis and treatment technology and management of neonatal inherited metabolic diseases screening for birth defects prevention and control was successfully held in Guangzhou from June 19 to 21.

On the 20th, Dr. Guo Yongchao, chairman of Uni-medica, was invited to share the theme of "Newborn Genetic Screening for Inherited Diseases". Dr. Guo's speech started with introducing the background of neonatal genetic metabolic disease, and then introduced the development and clinical application of newborn genetic screening for inherited metabolic diseases. With the development of modern medical technology, genetic testing has gradually become the first-line screening technology for neonatal inherited metabolic diseases.

Based on target gene combination (panel), next-generation sequencing technology can rapidly and comprehensively detect a variety of genetic diseases at one time, and has become the main way of assisting the clinical diagnosis of genetic diseases. The test results are not affected by nutrition, medication and other factors.

“Babyhealth” utilizes the patented “All-in-one” multiplex PCR amplicon library preparation technology and NGS technology. It performs exonic regions sequencing and analysis of more than 130 genes related to more than 120 metabolic and genetic diseases. The test is indicated for newborns and children. Offers early screening for genetic diseases that appear during the first stages of life, providing key information for preventive management, diet for early treatment. Early detection, intervention and management could prove essential for the infant's overall health and quality of life.

The Advantages

In the future, United Medical will continue to innovate and provide new products for newborn genetic disease screening, and is committed to becoming a leader in the field of precise prevention of birth defects.